ArticleDiscover oncology2026
PSMB1 screened by CRISPR-CAS9 promoted breast cancer progression via PI3K-AKT-mTOR signaling.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBreast cancer is a threat to women's health worldwide. Recent studies have focused on the role of differentially expressed genes in tumors. PSMB1 has been reported to play an important role in tumors, however, its role in breast cancer has not been well defined.
methodsThe CRISPR-CAS9 data was analyzed and intersected with Cox univariate analyzation to screen differentially expressed genes in breast cancer. The prognosis of PSMB1 was predicted by Kaplan-Meier plotter, and the related major pathways were analyzed through GO analysis and GSEA. PSMB1-related gene mutations and Tumor microenvironment characteristics were analyzed. The expression of PSMB1 in breast cancer tissues and cells were determined by RT-qPCR and IHC. MTT, colony formation assay, EdU, Transwell, wound healing assay and cell cycle assay were performed to observe its function in vitro. The western blot was conducted to detect its regulation on EMT markers and key proteins in PI3K pathway.
resultsIn this study, PSMB1 was screened by CRISPR-Cas9 and identified to be upregulated in breast cancer samples. By further analysis, PSMB1 was found to be involved in tumor-related biological process and correlated with worse prognosis in breast cancer patients. In vitro experiments verified that downregulation of PSMB1 could inhibit the malignant phenotype of breast cancer cells. The western blot showed that si-PSMB1 significantly decreased the expression of key proteins and their phosphorylation form in PI3K-AKT-mTOR signaling.
conclusionsi-PSMB1 inhibited breast cancer cell proliferation, invasion and migration probably by targeting PI3K-AKT-mTOR signaling, which brings innovative mechanisms for breast cancer regulation and emerging ideas for therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.